December 21, 2020
PA-20-183 - Research Project Grant (Parent R01 Clinical Trial Required)
PA-20-185 - Research Project Grant (Parent R01 Clinical Trial Not Allowed)
PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
PA-20-196 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
PA-20-262 - SBIR Omnibus/Parent Clinical Trial Required Funding Opportunity Announcement
PA-20-261 - STTR Omnibus/Parent Clinical Trial Required Funding Opportunity Announcement
PA-20-260 - SBIR Omnibus/Parent Clinical Trial Not Allowed Funding Opportunity Announcement
PA-20-265 - STTR Omnibus/Parent Clinical Trial Not Allowed Funding Opportunity Announcement
National Eye Institute (NEI)
The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the special interest of the NEI in research to identify new biomarkers and develop effective methods that can be used for the early diagnosis of dry eye disease (DED) and its subtypes, prognosis of disease progression, and monitoring of treatment response.
As defined by the Tear Film and Ocular Surface Society (TFOS), “Dry eye is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles.” (TFOS dry eye workshop, 2017). Prevalence estimates for DED range anywhere from 5% to 30% in individuals over the age of 50, with a higher prevalence in females. Despite the common occurrence of DED, diagnosis is challenging for diverse reasons, including the complicated etiologic mechanisms underlying the disease and poor correlation between clinical signs and symptoms. There is no well accepted gold standard to diagnose DED. Current diagnosis and clinical evaluation are often subjective and typically based on patient-reported symptoms. Since DED testing and/or treatments are not performed until a patient is symptomatic, current treatments for DED usually focus on resolving the symptoms, rather than on targeting the underlying cause of DED. There is a significant need for objective, validated, reliable, and reproducible diagnostic methods for DED.
This NOSI seeks to support investigation into effective methods to diagnose dry eye disease not based on whether symptoms are present. This includes the diagnosing and monitoring of DED in asymptomatic patients for developing clinical signs. A critical outcome is understanding applicability of the critical features of DED to aid in accurate diagnosis and effective treatment of DED.
This NOSI encourages, but is not limited to, research applications in the following areas:
Application and Submission Information
This notice applies to due dates on or after February 5, 2021 and subsequent receipt dates through May 8, 2023.
Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.
All instructions in theSF424 (R&R) Application Guide and the FOA used for submission must be followed, with the following additions:
Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.